Answers are grounded in this paper and cite their sources.
Our findings indicate that use of multiple measures of treatment adherence and persistence provides a more complete overview of medication use patterns, and certain limitations associated with DDD for some drug groups can be overcome with replacement by surrogate doses. The PDC indicator seems to provide a more accurate reflection of patient behavior and treatment continuity than the MPR. Any comparison of adherence/persistence should always consider the method used, variables analyzed, and corresponding data collection process.
No takes yet. Share an insight, caveat, or question.
Malo et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: